Daxor Corporation Common Stock (DXR)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a business with a durable competitive advantage, honest financials, and a price below intrinsic value. Daxor, at $10.35 on 2026-10-13, has a $59M market cap and sells the BVA-100 and Volumex. The idea is niche: measuring blood volume. That could matter clinically, but the filed figures I have are old and tiny: in fiscal 2011 revenue was $1.4M and net loss $7.2M; in fiscal 2010 revenue was $1.6M and net income $5.0M. Quarterly numbers are even lumpier: fiscal Q3 2011 revenue was $340,907 and net loss $4.2M, versus fiscal Q3 2010 revenue $453,281 and net income $2.6M. That is not the steady compounding I like. FairStock's calculations show a 9.41 P/E, 1.17 P/B, 14.24% ROE, but ROCE of -2.63%, a 0/9 Piotroski, and no dividend. The Graham Number is $14.82, giving a 30.16% margin of safety at the close, and beta 0.35 suggests low market sensitivity. Still, the lack of recent filed growth and a Lynch category of 'none'—only two years of filed results—means I cannot judge consistency. A low price-to-book and low P/E can be value traps if revenue is not recurring and profits are erratic. I would want evidence that BVA-100 adoption is rising, operating expenses are controlled, and cash is not being burned. Without that, this is a speculative medical-device microcap, not a Buffett-style compounder.

In plain English: Daxor makes a medical device and injection kit that measure blood volume. The business looks small and uneven: older filings show tiny revenue and swings between profit and loss, and recent data is limited. At $10.35, the shares look moderately cheap against the company's assets and a simple value estimate, but the business quality is mixed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2011 10-Q (period ended 2011-09-30) · fiscal Q3 2010 10-Q (period ended 2010-09-30) · FY2011 10-K (period ended 2011-12-31) · FY2010 10-K (period ended 2010-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer